Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

Pages

718 results
3:34 PM, Sep 17, 2018  |  BC Extra | Clinical News

Mersana gets green light to resume ADC trial, but new dosing may slow progress

Mersana Therapeutics Inc. (NASDAQ:MRSN) said it will resume a Phase I trial of antibody-drug conjugate XMT-1522 after FDA lifted a partial clinical hold on the trial. However, Mersana fell $3.24 (23%) to $11.14 seemingly in...
7:54 AM, Sep 11, 2018  |  BC Extra | Company News

Management tracks: Cheng joins Akero, bluebird COO leaving

venBio and Versant Ventures. The company's lead program, AKR-001, is a long-acting analog of fibroblast growth factor
12:45 PM, Sep 10, 2018  |  BC Extra | Clinical News

CARsgen solid tumor CAR T leads to complete response

member 17; TNFRSF17; CD269) for multiple myeloma, CD19 for B cell leukemia and lymphoma, EGFR/epidermal growth factor
7:07 PM, Sep 09, 2018  |  BC Extra | Financial News

With anti-VEGF challenger in clinic, Kodiak files for IPO

Ophthalmic company Kodiak Sciences Inc. (Palo Alto, Calif.) filed to raise $100 million in an IPO on NASDAQ underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Chardan. Using its antibody biopolymer conjugate (ABC) platform, Kodiak...
3:10 PM, Sep 06, 2018  |  BC Extra | Preclinical News

Dual therapy could treat AD -- if it can cross into clinic

Home for BDNF" ). Yet clinical trials of recombinant BDNF have disappointed, and the recombinant growth factor
1:28 PM, Sep 05, 2018  |  BC Extra | Company News

Chi-Med scores a China first with approval of fruquintinib

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said China's National Medical Products Administration (NMPA) approved Elunate fruquintinib to treat metastatic colorectal cancer (mCRC). According to Chi-Med, the drug is the first China-discovered and developed product for...
4:52 PM, Sep 04, 2018  |  BC Extra | Company News

How ex-GSK employee funneled trade secrets to Chinese company

necrosis factor α (TNFα), TNF receptor superfamily member 17 (BCMA; TNFRSF17; CD269), HER2 and fibroblast growth factor
11:04 AM, Sep 04, 2018  |  BC Extra | Company News

EC approves Puma's Nerlynx as adjuvant for breast cancer

The European Commission approved Nerlynx neratinib from Puma Biotechnology Inc. (NASDAQ:PBYI) for extended adjuvant treatment of adults with early hormone receptor-positive, HER2-overexpressed/amplified breast cancer within one year of completion of prior adjuvant Herceptin trastuzumab-based therapy....
2:49 PM, Aug 29, 2018  |  BC Extra | Preclinical News

Sequential therapies trigger axon regeneration in spinal cord injury

address the three mechanisms. First, an adeno-associated viral (AAV) vector delivered osteopontin (Opn; Spp1), insulin-like growth factor-1 …
spinal cord injury, the scientists injected hydrogel depots to the injury site to deliver fibroblast growth factor
2 (FGF2) and epidermal growth factor (EGF) to promote substrate production and glial cell-derived neurotrophic factor (GDNF …
8:32 AM, Aug 23, 2018  |  BC Extra | Financial News

Rakuten’s Mikitani leads Aspyrian's $150M series C

Rakuten Aspyrian Inc. (San Diego, Calif.) raised $150 million in a series C round led by Chairman Hiroshi Mikitani, who is CEO of Japanese e-commerce company Rakuten Inc. (Tokyo:4755). The round included other undisclosed private...

Pages